**Table S1.** General characteristics of patients with overt autoimmunity during post-COVID syndrome.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Autoimmune disease** | **Age (years)** | **Sex** | **Clinical manifestations of acute COVID-19a** | **Treatment of acute COVID-19** | **Clinical manifestations of autoimmune disease** | **Diagnostic test** | **Onset to autoimmunity (days)a** | **Positive microarray IgG antibodies** |
| Polymyositis | 39 | M | FeverAnosmia FatigueHeadacheDry coughSore throatDizzinessDiarrhea EmesisMyalgia | Patient required in-hospital management.Oxygen by cannulaprone positioncorticosteroidsAntibioticsThromboprophylaxis | Myalgiasproximal muscle weakness | CPK: 728 U/LElectromyography: Compatible with intrinsic muscle fiber disease, with evidence of proximal muscle involvement. | 220 | Anti-SARS-CoV-2 NCP, S1, S2, and RBD |
| Systemic lupus erythematosus | 25 | F | AnosmiaFatigueHeadache Dizziness Confusion MyalgiaArthralgiaMalaise | Patient required outpatient management.IvermectinLoratadineParacetamolCough syrup | ArthritisAstheniaFatigueChest painOral ulcersPhotosensitivity | Antinuclear antibodies (1/1280) homogeneous pattern (IFI)Serum complement C4: 7.60 mg/dL.Serum complement C3 60.90 mg/dL.dsDNA antibodies 1/2560 (Positive).Lupus anticoagulant ratio 1.5 (Positive).Mild leukopenia: 3250. | 26 | BAFF, BCOADC-E2/OGDC-E2/PDC-E2CalprotectinCENP-B, CENP-A,CMV, Collagen VIdsDNA, HistoneIFN- λ2/IL28A,IFN- λ3, Influenza BKu (p70/p80), LamininM2, Mi-2, NucleosomePM/Scl100, PR3, Ro/SS-A (52 + 60 kDa), SARS-CoV-2 S1 and S2, Scl-70/Topo Isomerase I, Sm, SP100, SRP54,Troponin I, U1-snRNP (68, A, C, B) |
| Autoimmune thyroid disease | 58 | F | Fatigue, Dry cough Sore throat Dyspnea | Patient required ICU managementAntibioticOxygen through high flow cannulacorticosteroidThromboprophylaxis | NAb | Anti-thyroglobulin antibodies: 0.18 IU (Negative - ELISA).anti-thyroid peroxidase antibodies: 101.39 IU (Positive - ELISA).Current management with Levothyroxine. | 257c | IFN- α/IFN-α1,IFN- α2, IFN- αA,Intrinsic factor (IF),Anti-SARS-CoV-2 S, S1, RBD, and S2 |

a Time from recovery to autoimmune disease onset.

b Patient with history of non-autoimmune hypothyroidism.

c Patient with prior history of hypothyroidism. During hospitalization for COVID-19, a serum sample was taken on August 29th, 2021. Anti-thyroid antibodies were negative. However, 257 days later, a new blood sample was taken. At this point, anti-thyroid peroxidase antibodies became positive.